Skip to main content

Table 2 Treatment characteristics and disease activity measures at baseline and at the infusion reaction in patients with RA and SpAs

From: Predictors of infusion reactions during infliximab treatment in patients with arthritis

Number At treatment initiation At infusion reaction
  RA (n = 213) SpA (n = 76) RA (n = 45) SpA (n = 10)
Drug treatments
   Infliximab monotherapy 46 (21.6%) 31 (40.8%) 22 (48.9%) 7 (70%)
   Methotrexate 129 (60.6%) 35 (46.1%) 17 (37.8%) 2 (20%)
   Sulphasalazine 33 (15.5%) 6 (7.9%) 5 (11.1%) 0
   Azathioprine 10 (4.7%) 3 (3.9%) 1 (2.2%) 0
   Other DMARDs 30 (14.1%) 4 (5.3%) 4 (8.9%) 1 (10%)
   Prednisolone 155 (72.8%) 30 (39.5%) 38 (84.4) 6 (60%)
Dosages
   Methotrexate (mg/week) 17.3 ± 5.2 15.6 ± 6.8 15.4 ± 6.1 16.2 ± 12.4
   Sulphasalazine (g/week) 13.5 ± 2.3 15.2 ± 2.9 15.4 ± 3.1 None
   Azathioprine (mg/week) 745.5 ± 432.1 758.3 ± 101.0 700 None
   Prednisolone (mg/week) 43.2 ± 37.8 20.5 ± 28.9 33.4 ± 29.0 11.7 ± 18.0
Disease activity measures
   DAS-28 5.4 ± 1.3 - 5.0 ± 1.6 -
   HAQ 1.4 ± 0.6 1.1 ± 0.6 1.3 ± 0.6 1.1 ± 0.8
   CRP 30.9 ± 33.4 21.7 ± 26.2 25.5 ± 26.3 14.4 ± 16.9
   ESR 36.8 ± 27.2 27.4 ± 23.0 37.8 ± 25.5 29.2 ± 32.1
   VASpain (0–100) 61.7 ± 22.2 61.4 ± 19.7 48.3 ± 25.7 55.9 ± 32.3
   VASglobal (0–100) 63.4 ± 21.6 63.4 ± 19.7 52.5 ± 25.4 56.3 ± 33.6
   Evaglobal (0–5) 2.3 ± 0.6 1.8 ± 0.7 1.9 ± 0.9 1.8 ± 0.6
   TJC (0–28) 8.7 ± 7.3 5.9 ± 6.9 7.9 ± 7.8 6.6 ± 8.3
   SJC (0–28) 8.9 ± 6.0 3.0 ± 4.1 6.9 ± 6.0 3.3 ± 5.4
  1. Values are expressed as mean ± standard deviation or as number (%). CRP, C-reactive protein; DAS-28, Disease Activity Score (using 28 tender and 28 swollen joint count); DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; Evaglobal, physicians global assessment; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; SJC, swollen joint count; SpA, spondylarthropathy; TJC, tender joint count; VASpain, patient's assessment of pain; VASglobal, patient's global assessment.